Anti-CAH14/ CA-XIV/ CA14 monoclonal antibody

Anti-CAH14/ CA-XIV/ CA14 antibody for FACS & in-vivo assay

Target products collectionGo to CA-XIV/CA14 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T31992-Ab-1/ GM-Tg-hg-T31992-Ab-2Anti-Human CA-XIV/CA14 monoclonal antibodyHuman
GM-Tg-rg-T31992-Ab-1/ GM-Tg-rg-T31992-Ab-2Anti-Rat CA-XIV/CA14 monoclonal antibodyRat
GM-Tg-mg-T31992-Ab-1/ GM-Tg-mg-T31992-Ab-2Anti-Mouse CA-XIV/CA14 monoclonal antibodyMouse
GM-Tg-cynog-T31992-Ab-1/ GM-Tg-cynog-T31992-Ab-2Anti-Cynomolgus/ Rhesus macaque CA-XIV/CA14 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T31992-Ab-1/ GM-Tg-felg-T31992-Ab-2Anti-Feline CA-XIV/CA14 monoclonal antibodyFeline
GM-Tg-cang-T31992-Ab-1/ GM-Tg-cang-T31992-Ab-2Anti-Canine CA-XIV/CA14 monoclonal antibodyCanine
GM-Tg-bovg-T31992-Ab-1/ GM-Tg-bovg-T31992-Ab-2Anti-Bovine CA-XIV/CA14 monoclonal antibodyBovine
GM-Tg-equg-T31992-Ab-1/ GM-Tg-equg-T31992-Ab-2Anti-Equine CA-XIV/CA14 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg

Product Description

Catalog No.GM-Tg-hg-T31992-Ab-1/ GM-Tg-hg-T31992-Ab-2; GM-Tg-rg-T31992-Ab-1/ GM-Tg-rg-T31992-Ab-2;
GM-Tg-mg-T31992-Ab-1/ GM-Tg-mg-T31992-Ab-2; GM-Tg-cynog-T31992-Ab-1/ GM-Tg-cynog-T31992-Ab-2;
GM-Tg-felg-T31992-Ab-1/ GM-Tg-felg-T31992-Ab-2; GM-Tg-cang-T31992-Ab-1/ GM-Tg-cang-T31992-Ab-2;
GM-Tg-bovg-T31992-Ab-1/ GM-Tg-bovg-T31992-Ab-2; GM-Tg-equg-T31992-Ab-1/ GM-Tg-equg-T31992-Ab-2
Products NameAnti-CA-XIV/CA14 monoclonal antibody
Target NameCA-XIV
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
Products descriptionPre-made anti-CA-XIV benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


    Data / case study

    Click to get more Data / Case study about the product.

    Associated products

    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species CAH14/ CA-XIV/ CA14 VLP (virus-like particle) (Products Developing)

    Target information

    Target IDGM-T31992
    Target NameCA-XIV
    Gene ID23632,23831,791259,706360,100855809,101082932,509027,100054535
    Gene Symbol and SynonymsCA-XIV,CA14,Car14,CAXiV
    Uniprot AccessionQ9ULX7
    Uniprot Entry NameCAH14_HUMAN
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target
    Gene EnsemblENSG00000118298
    Target ClassificationN/A

    The target: CA-XIV, gene name: CA14, also named as CAXiV. Carbonic anhydrases (CAs) are a large family of zinc metalloenzymes that catalyze the reversible hydration of carbon dioxide.  They participate in a variety of biological processes, including respiration, calcification, acid-base balance, bone resorption, and the formation of aqueous humor, cerebrospinal fluid, saliva, and gastric acid.  They show extensive diversity in tissue distribution and in their subcellular localization.  CA XIV is predicted to be a type I membrane protein and shares highest sequence similarity with the other transmembrane CA isoform, CA XII; however, they have different patterns of tissue-specific expression and thus may play different physiologic roles. [provided by RefSeq, Jul 2008].

    About Gmab


    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.